Zealand Pharma Says Phase 2 Petrelintide Study Met Primary Endpoint of Body Weight Reduction Versus Placebo

MT Newswires Live03-06

Zealand Pharma (ZEAL) said Thursday that its phase 2 trial of petrelintide met its primary endpoint, with once-weekly subcutaneous injections of petrelintide resulted in "statistically significant and clinically meaningful" reductions in body weight from baseline after 28 weeks compared to placebo.

The study further showed that body weight reduction was sustained through week 42, with participants achieving up to 10.7% mean reduction from baseline, compared to 1.7% with placebo, the biotechnology company said.

Zealand Pharma said that no unexpected safety signals were observed with petrelintide treatment and that the proportion of participants experiencing injection site reactions was consistent with placebo.

The phase 2 Zupreme-1 dose-finding trial evaluated petrelintide versus placebo in 493 people living with overweight and obesity for effects on body weight, safety, and tolerability, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment